Avid Bioservices Inc (CDMO)

[itsabouttime]

Bavi could assist in combo based on this information:

Barriers to T cell activation and attack

Targeted cancer therapies, designed to hit specific mutations on a cancer cell, come with ready-made predictive biomarkers. Patients whose tumors have the mutation receive the targeted therapy. In contrast, immune checkpoint blockade doesn’t directly target tumors. It treats the immune system, freeing it to find and kill cells bearing recognized tumor antigens.

Immune response, the authors note, particularly regulation of T cells, consists of opposing pathways both to stimulate immune response and to inhibit it. Ipilimumab blocks a molecule on T cells called CTLA-4, which is turned on by the same binding molecules, or ligands, that stimulate a T cell response. CTLA-4’s job is to block runaway immune response.

Once a T cell attack is launched, the review notes, it then faces a variety of barriers and defenses mounted by the tumor cells, supportive tissue, regulatory T cells and other inhibitory cells, as well as chemical signaling agents in the tumor microenvironment.